Nasdaq Biotechnology Ishares (IBB) 263.13 $IBB So Many

New Post Public Reply Private Reply Replies (0) Message Board

Mar 6, 2016 at 3:21 AM

Nasdaq Biotechnology Ishares (IBB) 263.13 $IBB

So Many Topics, So Few Columns
at The Street - Sat Mar 05, 11:00AM CST
In response to reader input, here's what to look for from me.
XBI: 51.94 (+0.22), IBB: 263.13 (-1.11), BAC: 13.54 (+0.04), GDX: 19.71 (-0.11)

5 Revenant Sectors Echo Leo's Oscar-Winning Performance
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 2:30PM CST
Like the determined Hugh Glass, these sectors stood up to escape a bear market following massive sell-offs at the start of the year and register solid gains over the past month.
AMZN: 575.14 (-2.35), UNH: 121.80 (-0.02), XLY: 76.72 (-0.07), DIS: 98.48 (-0.34), IBB: 263.13 (-1.11), XOM: 82.29 (-0.11), XLV: 67.41 (-0.16), JPM: 60.05 (+0.09), MRK: 52.08 (-0.02), DD: 63.18 (+1.27), XLFS: 28.45 (+0.13), BRK.B: 137.97 (+1.13), CVX: 87.93 (+0.40), DOW: 50.29 (+0.69)

Trader's Notebook: Is It Biotech's Turn to Outperform?
at The Street - Fri Mar 04, 8:00AM CST
The biotechnology sector has lagged horribly.
VALE: 4.38 (+0.27), XBI: 51.94 (+0.22), IBB: 263.13 (-1.11), TWI: 5.84 (+0.06)

Small Caps And Biotech Remain Weak Links Despite The Recent Rebound
Michael Harris - Seeking Alpha - Thu Mar 03, 1:40PM CST
In an article on June 20, 2015, I concluded that the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) and iShares Russell 2000 ETF (NYSEARCA: IWM ) were bubble markets, after analyzing their top 20 holding. Due to the correction that followed, IBB...
IBB: 263.13 (-1.11), IWM: 107.72 (+0.59)

These 3 Biotechs Are Growing Fast -- Which Is the Best Buy Today?
Brian Feroldi, The Motley Fool - Motley Fool - Thu Mar 03, 9:45AM CST
Image source: Juliacdrd via pixabay. We are only a quarter of the way through 2016, but it's already been a year that most biotechnology investors would rather forget. The iShares Nasdaq Biotechnology ETF , an exchange-traded fund that owns a...
VRTX: 88.36 (-1.09), ALXN: 144.46 (-1.39), IBB: 263.13 (-1.11), REGN: 403.82 (+1.88)

Why Celldex Therapeutics, Inc. and bluebird bio, Inc. Jumped Today
Brian Orelli, The Motley Fool - Motley Fool - Tue Mar 01, 3:26PM CST
What: A day after it fell a little over 10%, Celldex Therapeutics is up about 10% in the last hour of trading Tuesday after an analyst initiated coverage with a buy. On the other hand, bluebird bio is up about 10%, for apparently no reason....
BLUE: 54.50 (+0.63), CLDX: 8.19 (-0.06), IBB: 263.13 (-1.11)

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass
at The Street - Fri Feb 19, 8:00PM CST
Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.
TTPH: 4.35 (+0.13), SAGE: 34.01 (+0.36), ACAD: 21.20 (-0.26), XON: 37.03 (-0.25), AERI: 14.84 (-0.24), IBB: 263.13 (-1.11), CEMP: 17.52 (-0.19), AAPL: 103.01 (+1.51), NKTR: 11.35 (-0.09)

The Doomsday Loop
Dave Gonigam - Daily Reckoning - Fri Feb 19, 3:52PM CST
This post The Doomsday Loop appeared first on Daily Reckoning . Dave Gonigam's Rule of thumb: When central bankers fret, you should panic. Plus… Why ETFs will add fuel to the next market meltdown: A case study... The post The Doomsday Loop ...
IBB: 263.13 (-1.11)

ETFs at Risk of a Run
David Stockman - Daily Reckoning - Fri Feb 19, 7:52AM CST
This post ETFs at Risk of a Run appeared first on Daily Reckoning . David Stockman shows you why ETFs have become FEDs (financially explosive devices) that can go off at any time... The post ETFs at Risk of a Run appeared first on Daily...
GDP: 0.16 (-0.04), IBB: 263.13 (-1.11)

Why Keynesian Market Wreckers are Now Coming for Your Benjamins
David Stockman - Daily Reckoning - Thu Feb 18, 12:12PM CST
This post Why Keynesian Market Wreckers are Now Coming for Your Benjamins appeared first on Daily Reckoning . David Stockman shows you why ETFs have become FEDs (financially explosive devices) that can go off at any time... The post Why...
DAX: 23.22 (+0.18), GDP: 0.16 (-0.04), IBB: 263.13 (-1.11)

Generic ETF in Focus as Biotech Lose Charm
Zacks Equity Research - ZACKS - Wed Feb 17, 6:59AM CST
With biotech sector caught in a nasty web of lingering headwinds, this generic ETF invites attention.
AGN: 288.67 (-0.95), JNJ: 106.50 (-0.15), GNRX: 24.10 (unch), AZN: 28.87 (+0.13), PFE: 29.71 (-0.18), XBI: 51.94 (+0.22), AMGN: 145.98 (+0.14), MYL: 44.78 (-0.95), IBB: 263.13 (-1.11), TEVA: 55.62 (+0.02), GSK: 39.14 (-0.04), NVS: 72.20 (-0.75)

3 Biotech Stocks to Buy in a Market Crash
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 09, 8:23PM CST
Source: Flickr user Elliott Brown. Gilead Sciences , Celgene Corp. , and Regeneron Pharmaceuticals aren't immune to market whims and whispers, but they do share one thing in common; a track record for developing multibillion dollar...
GILD: 87.21 (-0.62), MRK: 52.08 (-0.02), IBB: 263.13 (-1.11), ABBV: 56.15 (+0.22), REGN: 403.82 (+1.88), CELG: 102.51 (-0.22)

Biotech ETFs Slide as Stocks Report Mixed Q4 Results
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 12:48PM CST
Thanks to mixed results, the biotech sector has failed to gain investor confidence so far in the fourth quarter.
PBE: 38.64 (-0.12), BIIB: 263.94 (-4.70), GILD: 87.21 (-0.62), FBT: 88.37 (+0.55), ALXN: 144.46 (-1.39), BBH: 103.52 (-0.23), IBB: 263.13 (-1.11), AMGN: 145.98 (+0.14), CELG: 102.51 (-0.22)

3 Reasons Why Celgene Corp.'s Stock Dropped 15% in January
George Budwell, The Motley Fool - Motley Fool - Tue Feb 09, 8:05AM CST
CELG data by YCharts What: The blue-chip biotech Celgene Corp. lost nearly 15% of its value last month, according to data provided by S&P Global Market Intelligence . Celgene's stock was walloped by the changing market sentiment toward...
IBB: 263.13 (-1.11), CELG: 102.51 (-0.22)

20.5% Return Seen to Date on SmarTrend iShares Nasdaq Biotechnology Index Call (IBB)
Comtex SmarTrend(R) - Mon Feb 08, 5:48PM CST
SmarTrend identified a Downtrend for iShares Nasdaq Biotechnology Index (AMEX:IBB) on January 7th, 2016 at $311.98. In approximately 1 month, iShares Nasdaq Biotechnology Index has returned 20.54% as of today's recent price of $247.91.
IBB: 263.13 (-1.11)

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 3.25%
Comtex SmarTrend(R) - Mon Feb 08, 5:27PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $243.80 to a high of $251.81. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $251.63 on volume of 3.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 263.13 (-1.11)

iShares Nasdaq Biotechnology Index Falls 3.25% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 08, 5:26PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $243.80 to a high of $251.81. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $251.63 on volume of 3.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 263.13 (-1.11)

The Key Takeaways From Alexion Pharmaceuticals Inc.'s Earnings Release
Brian Feroldi, The Motley Fool - Motley Fool - Fri Feb 05, 4:57PM CST
Image by TBIT via Pixabay. Biotech heavyweight Alexion Pharmaceuticals released its fourth-quarter 2015 earnings results before the opening bell Wednesday. Like many other biotechs, Alexion's shares have taken a beating recently, as they have...
ALXN: 144.46 (-1.39), IBB: 263.13 (-1.11)

Why Did Biotech Fall Off a Cliff in January?
George Budwell, The Motley Fool - Motley Fool - Thu Feb 04, 7:59AM CST
Biotech stocks started the year off on the wrong foot (to put it mildly). While the S&P 500 shed a little over 5% during January, the iShares Nasdaq Biotechnology ETF dropped by a whopping 21% last month, according to data provided by ...
GILD: 87.21 (-0.62), SRPT: 14.29 (+0.02), CLDX: 8.19 (-0.06), IBB: 263.13 (-1.11), ALKS: 32.58 (-0.33), CELG: 102.51 (-0.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lawsuit Highlights Inaction in School Bus Tragedy

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...

Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

Monteverde Probes Four Key M&A Deals for Fairness

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

Power Knot MEA Wins THE BIZZ 2026 for Excellence

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Black Culture Icon: Plastic-Covered Couch Takes Stage

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Monster Energy Dominates Skateboard Podium at SLS Paris

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Blokees Unveils 90+ New Wonders at Shanghai Fest

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...